Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-l.

Masimo to Present in the Jefferies London Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industr.

Masimo to Present in Stifel 2024 Healthcare Conference

Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.

MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands

Masimo Corporation (NASDAQ:MASI ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Eli Kammerman - VP of Business Development and IR Michelle Brennan - Interim CEO Micah Young - EVP and CFO Bilal Muhsin - COO Conference Call Participants Jason Bednar - Piper Sandler Marie Thibault - BTIG Michael Polark - Wolfe Research Frederick Wise - Stifel Matt Taylor - Jefferies Vik Chopra - Wells Fargo Michael Matson - Needham Jayson Bedford - Raymond James Operator Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com.

Masimo Corporation (MASI) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Masimo (MASI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Masimo (MASI) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.63 per share a year ago.

Masimo (MASI) Q3 Earnings and Revenues Top Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8 million. GAAP net income wa.

Masimo Reports Third Quarter 2024 Financial Results

Beyond analysts' top -and-bottom-line estimates for Masimo (MASI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Exploring Analyst Estimates for Masimo (MASI) Q3 Earnings, Beyond Revenue and EPS

Medical-device maker said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company, following a review by outside counsel.

Masimo Terminates Founder Kiani as CEO

Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth

IRVINE, Calif.--(BUSINESS WIRE)--Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring technology in the ED.

Vanderbilt University Medical Center Integrates Masimo Radius VSM™ in Proactive Care Protocol to Combat Emergency Room Congestion

Apple

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn't getting a big payday.

Apple wins $250 from Masimo in watch patent trial

Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents.

Masimo smartwatches infringe Apple design patents, US jury says

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer. To register for the conference ca.

Masimo to Report Third Quarter 2024 Financial Results after Market Close on Tuesday, November 5

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the “Board”), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, “We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals.

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Masimo (MASI) is a Top Momentum Stock for the Long-Term

Travere Therapeutics

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

MASI's R&D activities raise optimism about the stock.

Here's Why You Should Add Masimo Stock to Your Portfolio Now

Anglogold Ashanti Plc

SK Telecom Co., Ltd.

AU, MASI, and SKM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 1, 2024.

Best Momentum Stocks to Buy for October 1st

The medical technology specialist, known for its monitoring devices, named an interim CEO. This followed the resignation of its existing chief.

Why Masimo Stock Crushed the Market Today

Masimo stock jumped Wednesday after Chief Executive Joe Kiani resigned. But, importantly, the company's other executives stayed on board.

Masimo CEO Joe Kiani Resigns Following Politan Proxy Battle; Shares Jump

Masimo said on Wednesday that Joe Kiani has decided to resign as CEO, days after shareholders voted to remove him from the company's board.

Masimo's Joe Kiani resigns as CEO after board ouster

IRVINE, Calif.--(BUSINESS WIRE)--Today the Board of Directors (the “Board”) of Masimo (Nasdaq: MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer (“CEO”) following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareholders at the recent Annual Meeting, Darlene Solomo.

Masimo Provides Leadership and Business Updates

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for Masimo Stock (MASI)